RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets hard-to-treat blood cancers
Disease control Not yet recruitingThis study tests two drugs, adebrelimab and SHR2554, together in about 40 adults whose T-cell lymphoma has come back or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have certain types of T-cell lymphom…
Matched conditions: RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough lymphoma: drug combo trial launches
Disease control Not yet recruitingThis study tests a combination of two drugs, mitoxantrone hydrochloride liposome and enlonstobart, in people with peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to find the safest and most effective dose and see how well the combo works. …
Matched conditions: RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC